Quality assessment of clinical practice guidelines for chronic kidney disease: a systematic review.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
28 05 2019
Historique:
received: 30 08 2017
accepted: 15 05 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 1 9 2020
Statut: epublish

Résumé

Chronic kidney disease (CKD) is a worldwide public health problem. Clinical practice guidelines (CPGs) are being developed and implemented in order to improve clinical practice related to the detection and treatment of CKD. The objective of our study was to evaluate the quality of CPGs regarding the CKD and to examine whether there are factors which influence their quality. A systematic search was conducted to identify all CPGs regarding the early diagnosis and treatment of CKD. The CPGs quality were evaluated by three reviewers using the AGREE II instrument to decide if the guidelines are recommended for their use in clinical practice. In total, 13 CPGs were identified: five from America, six from Europe, one from Asia, and one from Oceania. Five CPGs were recommended for their use in clinical practice; since all their domains achieved the medium or high category. Furthermore, six CPGs were recommended with modifications, as the stakeholders' involvement, applicability, and editorial independence domains were evaluated as low category. These domains, as well as the rigor of the development domain, reached the very low category in those CPGs that were not recommended for its use in clinical practice. In all CPGs, the domains with the lowest average were the stakeholder involvement and the applicability. When comparing the domains of the CPGs according to the origin, type of developer group, the checklist used during the development and the publication period, a significantly higher average in the domain stakeholder involvement was found in the CPGs from Asia and Oceania compared to the ones in Latin America. Additionally, a significantly higher average in the applicability domain was found in the CPGs developed by CPGs developer organizations compared to those developed by medical societies. In total, 85% of the CPGs regarding CKD were recommended or recommended with modifications. The stakeholder involvement and applicability domains are assessed in the low category, which might affect the CPGs implementation. In order to save resources in low- and middle-income countries, an adaptation of the recommended CPGs should be considered.

Sections du résumé

BACKGROUND
Chronic kidney disease (CKD) is a worldwide public health problem. Clinical practice guidelines (CPGs) are being developed and implemented in order to improve clinical practice related to the detection and treatment of CKD. The objective of our study was to evaluate the quality of CPGs regarding the CKD and to examine whether there are factors which influence their quality.
METHODS
A systematic search was conducted to identify all CPGs regarding the early diagnosis and treatment of CKD. The CPGs quality were evaluated by three reviewers using the AGREE II instrument to decide if the guidelines are recommended for their use in clinical practice.
RESULTS
In total, 13 CPGs were identified: five from America, six from Europe, one from Asia, and one from Oceania. Five CPGs were recommended for their use in clinical practice; since all their domains achieved the medium or high category. Furthermore, six CPGs were recommended with modifications, as the stakeholders' involvement, applicability, and editorial independence domains were evaluated as low category. These domains, as well as the rigor of the development domain, reached the very low category in those CPGs that were not recommended for its use in clinical practice. In all CPGs, the domains with the lowest average were the stakeholder involvement and the applicability. When comparing the domains of the CPGs according to the origin, type of developer group, the checklist used during the development and the publication period, a significantly higher average in the domain stakeholder involvement was found in the CPGs from Asia and Oceania compared to the ones in Latin America. Additionally, a significantly higher average in the applicability domain was found in the CPGs developed by CPGs developer organizations compared to those developed by medical societies.
CONCLUSIONS
In total, 85% of the CPGs regarding CKD were recommended or recommended with modifications. The stakeholder involvement and applicability domains are assessed in the low category, which might affect the CPGs implementation. In order to save resources in low- and middle-income countries, an adaptation of the recommended CPGs should be considered.

Identifiants

pubmed: 31138205
doi: 10.1186/s12882-019-1387-x
pii: 10.1186/s12882-019-1387-x
pmc: PMC6540562
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

192

Références

Adv Chronic Kidney Dis. 2005 Oct;12(4):418-23
pubmed: 16198282
Nephron Clin Pract. 2011;118 Suppl 1:c71-c100
pubmed: 21555905
BMJ. 2016 Mar 08;352:i1152
pubmed: 26957104
Am J Kidney Dis. 2007 Feb;49(2):175-9
pubmed: 17261418
Implement Sci. 2015 Mar 15;10:36
pubmed: 25885412
CMAJ. 2010 Dec 14;182(18):E839-42
pubmed: 20603348
Am J Alzheimers Dis Other Demen. 2013 Mar;28(2):111-9
pubmed: 23288575
Ann Intern Med. 2013 Dec 17;159(12):835-47
pubmed: 24145991
BMJ Open. 2015 Jul 15;5(7):e008099
pubmed: 26179649
Nephrology (Carlton). 2013 Sep;18(9):592-604
pubmed: 23815515
Qual Saf Health Care. 2003 Feb;12(1):18-23
pubmed: 12571340
Qual Saf Health Care. 2010 Dec;19(6):e58
pubmed: 21127089
BMJ Open. 2015 Feb 18;5(2):e007047
pubmed: 25694459
Int Urol Nephrol. 2017 Feb;49(2):273-284
pubmed: 27804080
J Clin Epidemiol. 2015 May;68(5):498-509
pubmed: 25684154
Implement Sci. 2011 Mar 22;6:26
pubmed: 21426574
J Biomed Inform. 2001 Feb;34(1):52-66
pubmed: 11376543
Kidney Int. 2016 Dec;90(6):1164-1174
pubmed: 27884311
Nefrologia. 2008;28(3):273-82
pubmed: 18590493
Implement Sci. 2014 Aug 05;9:98
pubmed: 25091091

Auteurs

Jorge Coronado Daza (J)

Facultad de Medicina, Universidad de Cartagena, Cartagena, 130014, Colombia. jocodada@yahoo.es.
Nefrologia y Diálisis SAS, Cartagena, 130001, Colombia. jocodada@yahoo.es.

Robin W M Vernooij (RWM)

Iberoamerican Cochrane Centre, 08041, Barcelona, Spain.
Biomedical Research Institute Sant Pau, 08025, Barcelona, Spain.

Karla Salas (K)

Hospital de la Santa Creu i Sant Pau, 08041, Barcelona, Spain.

Dimelza Osorio (D)

University Hospital Vall d'Hebron, 08035, Barcelona, Spain.

Gerard Urrútia Cuchí (G)

Iberoamerican Cochrane Centre, 08041, Barcelona, Spain.
Biomedical Research Institute Sant Pau, 08025, Barcelona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH